A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey +1 locations
Conditions: Psoriasis, Overweight or Obesity
A Study of a Weight Loss Intervention in People With Endometrial Cancer
Recruiting
The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +2 locations
Conditions: Endometrial Cancer
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Recruiting
This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment. Secondary objectives include evaluating 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey +6 locations
Conditions: Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer